Top-line final data from Provectus’ PV-10 phase 2 trial on metastatic melanoma

[News]

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that top-line final data from its phase 2 clinical trial of PV-10 for metastatic melanoma were presented at the 2nd European Post-Chicago Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.

More... (http://www.news-medical.net/news/20120627/Top-line-final-data-from-Provectuse28099-PV-10-phase-2-trial-on-metastatic-melanoma.aspx)